Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924638 · ClinicalTrials.gov registry record · Phase 4
Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
A Phase 4 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 4
- Development phase
- 447
- Enrollment target
NCT00924638: Completed Phase 4 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00924638 is a Phase 4 study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 447 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00924638, a Phase 4 study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 447 participants
- Enrollment target
Study Summary
The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in order to prevent a second stroke. When a stroke patient is found to have atrial fibrillation (AF), the guidelines recommend oral anticoagulation due to its superior efficacy over aspirin for stroke prevention. Physicians can best optimize the use of medicines only if they can precisely and correctly diagnose a patient's AF. The purpose of this study is to evaluate the time to first AF by 6 months' continuous rhythm monitoring versus control treatment in subjects with a recent cryptogenic stroke or Transient Ischemic Attack (TIA) without history of AF.
Primary Outcome
Percentage of subjects with AF detected within 6 months of follow-up
Interventions
- DEVICE Reveal® XT Insertable Cardiac Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
What the finished NCT00924638 record still lists
NCT00924638 is an interventional study that assigns participants to a tested intervention. The registered 447 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 1 intervention - of which Reveal® XT Insertable Cardiac Monitor is the first listed.
NCT00924638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00924638 about?
NCT00924638 is a clinical study titled "Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke". The 2006 American Heart Association / American Stroke Association Council on Stroke Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in order to prevent a second strok...
What is the current status of trial NCT00924638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 447 participants. The study started on 2009-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00924638?
The interventions under investigation include: Reveal® XT Insertable Cardiac Monitor (DEVICE).
Who is sponsoring clinical trial NCT00924638?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00924638's enrollment target sits among peer trials
447 188th of 2000 higher than 1,812 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia